Stock 4583 CHIOME BIOSCIENCE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Chiome Bioscience Inc.

Equities

4583

JP3205350006

Delayed Japan Exchange
Other stock markets
 08:33:11 2024-04-24 pm EDT 		5-day change 1st Jan Change
126 JPY -0.79% Intraday chart for Chiome Bioscience Inc. -3.08% -6.67%
Apr. 01 Chiome Bioscience Cancels License Agreements with ADC Therapeutics MT
Feb. 13 Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Chiome Bioscience Cancels License Agreements with ADC Therapeutics
MT
Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited
CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Chiome Bioscience Inc. announced that it has received ¥13.49304 million in funding from Barclays Bank PLC (Tokyo Branch), Growth Capital, Inc.
CI
Chiome Bioscience Inc. announced that it expects to receive ¥13.49304 million in funding
CI
Chiome Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Chiome Bioscience Inc. Provided Sales Guidance for 2023
CI
Henlius Biotech Terminates License Agreement for Chiome Bioscience's Tumor Drug
MT
Chiome Bioscience Inc. Announces Termination of the License Agreement for Anti-TROP-2 Antibody Development and Commercialization with Shanghai Henlius Biotech, Inc
CI
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Chiome Bioscience Reports Results of Cancer Immunotherapy Joint Research
MT
Chiome Bioscience Signs Research and Option Agreement with Heidelberg Pharma
MT
Heidelberg Pharma Enters Research Collaboration Deal With Japan's Chiome Bioscience
MT
Chiome Bioscience : Announcement of target-specific research and option agreement with Heidelberg Pharma
PU
Chiome Bioscience Inc. Announces Conclusion of Target-Specific Research and Option Agreement with Heidelberg Pharma
CI
Japan Index Snaps Three-day Winning Streak on Inflationary Pressures; Kudan Shares Expand 7%
MT
Chiome Bioscience, Rohto Pharmaceutical Sign Deal for Generation of Therapeutic Antibody
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4583 Stock
  4. News Chiome Bioscience Inc.